TABLE 2.

Proportional use^a of chimeric CCR5:CXCR4 chemokine coreceptors by ADA-3 envelope mutants

Mutation or mutation combination	5555	5554	5545	4555	4444
0	100
1	100
2	100
3	100
4	100
5	100
1, 2	100
1, 3	99.91				0.09
1, 4	98.12				1.88
1, 5	99.23			0.77
2, 3	100
2, 4	100
2, 5	100
3, 4	100
3, 5	100
4, 5	100
1, 2, 3	100
1, 2, 4	100
1, 2, 5	99.32		0.48		0.21
1, 3, 4	96.87		2.24	0.30	0.59
1, 3, 5	99.12		0.29	0.31	0.27
1, 4, 5	86.99				13.01
2, 3, 4	100
2, 3, 5	100
2, 4, 5	77.95		16.19	5.86
3, 4, 5	62.45		17.68	10.26	9.60
1, 2, 3, 4	98.87				1.13
1, 2, 3, 5	99.51			0.49
1, 2, 4, 5	69.19		11.27	7.46	12.07
1, 3, 4, 5	76.85	3.15	10.22	2.58	7.19
2, 3, 4, 5	75.71		11.34	8.58	4.37
1, 2, 3, 4, 5	74.71	0.53	14.13	4.63	6.00

^aNumbers represent the percentage of total infection mediated by one chemokine receptor compared to infection mediated by all coreceptors. Note that the level of infectivity of each mutant is shown in Fig. 1 and is not taken into account in calculating the relative use of each parental or chimeric coreceptor.